Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2Sarcoma 1

Conditions

Urinary Bladder Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Glioma 4Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Carcinoma, Transitional Cell 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2LY3023414 2talazoparib 1olaparib 1irinotecan sucrosofate 1amino-acid, glucose, and electrolyte solution 1Vemurafenib 1Temozolomide 1Pharmacogenomic Variants 1Liquid Biopsy 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × erdafitinib × 90 days × Clear all
NCT03210714 2026-05-12

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03155620 2026-05-05

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡